


FORM PTO-1390 (REV. 10-2003)		U.S. DEPARTMENT OF COMMERCE AND PATENT AND TRADEMARK OFFICE	
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER <b>2003946-0110 (ANDI/US)</b>	
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>NOT YET ASSIGNED</b> <span style="font-size: 1.5em; font-weight: bold;">10/507067</span>	
INTERNATIONAL APPLICATION NO. <b>PCT/US03/07377</b>	INTERNATIONAL FILING DATE <b>March 7, 2003</b>	PRIORITY DATE CLAIMED <b>March 8, 2002</b>	
TITLE OF INVENTION <b>MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS</b>			
APPLICANT(S) FOR DO/EO/US <b>Boivin, et al.</b>			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.			
2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.			
3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.			
4. <input checked="" type="checkbox"/> The US has been elected (Article 31).			
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c)(2))			
a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau) <b>PCT/US03/07377, Application as filed (422 pp.) with Appendix A (10 pp. including cover sheet)</b>			
b. <input type="checkbox"/> has been communicated by the International Bureau.			
c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).			
6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).			
a. <input type="checkbox"/> is attached hereto.			
b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).			
7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)).			
a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).			
b. <input type="checkbox"/> have been communicated by the International Bureau.			
c. <input type="checkbox"/> have not been made; however, the time limit for making such amendment has NOT expired.			
d. <input type="checkbox"/> have not been made and will not be made.			
8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).			
9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. (c)(4)) ( <b>20 pp.</b> )			
10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).			
<b>Items 11 to 20 below concern document(s) or information included:</b>			
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. ( <b>66 pp.</b> )			
13. <input checked="" type="checkbox"/> A preliminary amendment. ( <b>34 pp.</b> )			
14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.			
15. <input type="checkbox"/> A substitute specification.			
16. <input checked="" type="checkbox"/> A power of attorney and/or change of address letter. ( <b>1 pg.</b> )			
17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825.			
18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).			
19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).			
20. <input checked="" type="checkbox"/> Other items or information:			
<input checked="" type="checkbox"/> <b>Appendix B – PCT Article 34 Amendment filed December 15, 2003 (27 pp. including cover sheet)</b>			
<input checked="" type="checkbox"/> <b>Appendix C – PCT Article 34 Amendment filed April 28, 2004 (87 pp. including cover sheet)</b>			
<input checked="" type="checkbox"/> <b>Appendix D – International Preliminary Examination Report (54 pp. including cover sheet)</b>			
<input checked="" type="checkbox"/> <b>Appendix E – International Search Report (8 pp. including cover sheet)</b>			
<input checked="" type="checkbox"/> <b>Establishing Right of Assignee to Take Action (37 CFR § 3.73(b)) (3 pp.)</b>			
<input checked="" type="checkbox"/> <b>Return Postcard</b>			
<input checked="" type="checkbox"/> <b>Certificate of Express Mailing (1 pg.)</b>			

U.S. APPLICATION NO. <b>2003/507067</b> NOT YET ASSIGNED		INTERNATIONAL APPLICATION NO. PCT/US03/07377		ATTORNEY'S DOCKET NUMBER 2003946-0110 (ANDI/US)		
21. <input checked="" type="checkbox"/> Other items or information: <b>BASIC NATIONAL FEE (37 CFR 1.492 (A) (1) - (5)):</b>				<b>CALCULATIONS PTO USE ONLY</b>		
Neither international examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1080.00						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$920.00						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$770.00						
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$730.00						
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00						
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$ 920.00</b>		
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				<b>\$</b>		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			
Total claims	86 - 20 =	66	66 x \$18.00	\$1,188.00		
Independent claims	5 - 3 =	2	2 x \$86.00	\$ 172.00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$290.00	\$ 290.00		
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$2,570.00</b>		
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				<b>\$</b>		
<b>SUBTOTAL =</b>				<b>\$2,570.00</b>		
Processing fee of <b>\$130.00</b> for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				<b>\$</b>		
<b>TOTAL FEES ENCLOSED =</b>				<b>\$2,570.00</b>		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				<b>\$ 40.00</b>		
<b>TOTAL FEES ENCLOSED =</b>				<b>\$2,610.00</b>		
				<b>Amount to be refunded:</b>	<b>\$</b>	
				<b>charged:</b>	<b>\$</b>	
a. <input checked="" type="checkbox"/> A check in the amount of <b>\$\$2,610.00</b> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 03-1721 in the amount of \$ to cover the above fees. A supplicate copy of this sheet is enclosed c. <input checked="" type="checkbox"/> The Commisssioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 03-1721. <b>A duplicate of this sheet is enclosed.</b> d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.						
<b>NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a)          or (b)) must be filed and granted to restore the application to pending status.</b>						
<b>SEND ALL CORRESPONDENCE TO:</b>  Patent Group Choate, Hall & Stewart Exchange Place 53 State Street Boston, Massachusetts 02109						
				 SIGNATURE <b>Nadège M. Lagneau, Ph.D.</b> NAME <b>51,908</b> REGISTRATION NUMBER		

10/507067

ATTORNEY DOCKET No.: 2003946-0110 (ANDI/US) DT09 Rec'd PCT/PTO 08 SEP 2004

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


Applicant: Boivin, *et al.* Examiner: NYA.  
Serial No: NYA Group Art Unit: NYA  
Filing Date: September 8, 2004  
Corresp. to: PCT/US03/07377  
Int. Filing Date: March 7, 2003  
Earliest Priority: March 8, 2002  
Title: MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS

Mail Stop: PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**Certificate of Express Mailing**

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as "*Express Mail Post Office to Addressee*" service under 37 C.F.R. 1.10 in an envelope addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date of September 8, 2004.

  
\_\_\_\_\_  
Nadège M. Lagneau  
Express Mail No.: EV 314103555 US